Skip to content

Rilpivirine + darunavir HIV maintenance regimen matches standard three-drug antiretroviral therapy

Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health

Tony Mills at IAS 2015. Photo by Liz Highleyman, hivandhepatitis.com

New NNRTI doravirine suppresses HIV as well as efavirenz but with fewer central nervous system side-effects

Dr José Gatell at IAS 2015. Photo by Liz Highleyman, hivandhepatitis.com

Five antiretroviral combinations associated with increased risk of a cardiovascular event

Ritonavir concentrations not correlated with lipid levels in people with HIV taking boosted atazanavir or boosted darunavir

Chinese study sheds light on how well treatment may work as prevention in the real world

Most HIV-positive gay men in European survey are on HIV treatment, though fewer in the east

Does HIV make you fat? Study connects viral load with fat gains

Tenofovir, boosted atazanavir and boosted lopinavir are associated with cumulative risk of developing chronic kidney disease